Chronic constriction injury reduces cannabinoid receptor 1 activity in the rostral anterior cingulate cortex of mice.
The present studies examined the effect of chronic neuropathic pain on cannabinoid receptor density and receptor-mediated G-protein activity within supraspinal brain areas involved in pain processing and modulation in mice. Chronic constriction injury (CCI) produced a significant decrease in WIN 55,212-2-stimulated [(35)S]GTPgammaS binding in membranes prepared from the rostral anterior cingulate cortex (rACC) of CCI mice when compared to sham-operated controls. Saturation binding with [(3)H]SR 141716A in membranes of the rACC showed no significant differences in binding between CCI and sham mice. Analysis of levels of the endocannabinoids anandamide (AEA) or 2-arachidonoylglycerol (2-AG) in the rACC following CCI showed no significant differences between CCI and sham mice. These data suggest that CCI produced desensitization of the cannabinoid 1 receptor in the rACC in the absence of an overall decrease in cannabinoid 1 receptor density or change in levels of AEA or 2-AG. These data are the first to show alterations in cannabinoid receptor function in the rostral anterior cingulate cortex in response to a model of neuropathic pain.
Hoot
Michelle R
MR
Virginia Commonwealth University, Department of Pharmacology and Toxicology, Richmond, VA, USA.
Sim-Selley
Laura J
LJ
Poklis
Justin L
JL
Abdullah
Rehab A
RA
Scoggins
Krista L
KL
Selley
Dana E
DE
Dewey
William L
WL
D000700:Analgesics; D000818:Animals; D001095:Arachidonic Acids / Q000378:metabolism; D048588:Benzoxazines / Q000378:metabolism; D063385:Cannabinoid Receptor Modulators; D002462:Cell Membrane / Q000378:metabolism; D003250:Constriction; D004195:Disease Models, Animal; D063388:Endocannabinoids; D005989:Glycerides; D016244:Guanosine 5'-O-(3-Thiotriphosphate); D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D008959:Models, Neurological; D009025:Morpholines / Q000378:metabolism; D009281:Naphthalenes / Q000378:metabolism; D010146:Pain / Q000378:metabolism* / Q000503:physiopathology; D010880:Piperidines; D053284:Polyunsaturated Alkamides / Q000378:metabolism; D017397:Prefrontal Cortex / Q000293:injuries / Q000378:metabolism* / Q000503:physiopathology; D011720:Pyrazoles; D043884:Receptor, Cannabinoid, CB1 / Q000378:metabolism* / Q000502:physiology*; D000077285:Rimonabant; D013462:Sulfur Radioisotopes; D014316:Tritium
D000700:Analgesics; D001095:Arachidonic Acids; D048588:Benzoxazines; D063385:Cannabinoid Receptor Modulators; D063388:Endocannabinoids; D005989:Glycerides; D009025:Morpholines; D009281:Naphthalenes; D010880:Piperidines; D053284:Polyunsaturated Alkamides; D011720:Pyrazoles; D043884:Receptor, Cannabinoid, CB1; D013462:Sulfur Radioisotopes; D014316:Tritium; D016244:Guanosine 5'-O-(3-Thiotriphosphate); C070417:(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone; C094503:glyceryl 2-arachidonate; D000077285:Rimonabant; C078814:anandamide